Trofosfamide

Trofosfamide (INN) is a nitrogen mustard alkylating agent. It is sometimes abbreviated "TRO".[1] It has been used in trials to study its effects on Ependymomas, Medulloblastomas, Sarcoma, Soft Tissue, Supratentorial PNETs, and Recurrent Brain Tumors.[2]

Trofosfamide

Clinical data
Trade names	Ixoten
AHFS/Drugs.com	International Drug Names
Routes of administration	By mouth (film-coated tablets)
ATC code	L01AA07 (WHO)
Legal status
Legal status	DE: § 48 AMG/§ 1 MPAV (Prescription only)
Identifiers
IUPAC name N,N,3-tris(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amide 2-oxide
CAS Number	22089-22-1^Y
PubChem CID	65702
ChemSpider	59129^N
UNII	H64JRU6GJ0
KEGG	D07252^Y
ChEMBL	ChEMBL462019^N
ECHA InfoCard	100.040.686
Chemical and physical data
Formula	C9H18Cl3N2O2P
Molar mass	323.58 g·mol^−1
3D model (JSmol)	Interactive image
SMILES C1CN(P(=O)(OC1)N(CCCl)CCCl)CCCl
InChI InChI=1S/C9H18Cl3N2O2P/c10-2-6-13-5-1-9-16-17(13,15)14(7-3-11)8-4-12/h1-9H2^N Key:UMKFEPPTGMDVMI-UHFFFAOYSA-N^N
^NY (what is this?)  (verify)

References

1. Jahnke K, Thiel E, Bechrakis NE, et al. (December 2008). "Ifosfamide or trofosfamide in patients with intraocular lymphoma". J. Neurooncol. 93 (2): 213–7. doi:10.1007/s11060-008-9761-8. PMID 19099202.
2. "Trofosfamide". www.drugbank.ca. Retrieved 2019-12-19.